BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11446343)

  • 1. DNA methylation in breast cancer.
    Yang X; Yan L; Davidson NE
    Endocr Relat Cancer; 2001 Jun; 8(2):115-27. PubMed ID: 11446343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic alterations in gastric carcinogenesis.
    Choi IS; Wu TT
    Cell Res; 2005 Apr; 15(4):247-54. PubMed ID: 15857579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics and breast cancer.
    Asch BB; Barcellos-Hoff MH
    J Mammary Gland Biol Neoplasia; 2001 Apr; 6(2):151-2. PubMed ID: 11501575
    [No Abstract]   [Full Text] [Related]  

  • 4. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation changes in leukaemia.
    Melki JR; Clark SJ
    Semin Cancer Biol; 2002 Oct; 12(5):347-57. PubMed ID: 12191634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation and cancer therapy.
    Szyf M
    Drug Resist Updat; 2003 Dec; 6(6):341-53. PubMed ID: 14744498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stilbenoids remodel the DNA methylation patterns in breast cancer cells and inhibit oncogenic NOTCH signaling through epigenetic regulation of MAML2 transcriptional activity.
    Lubecka K; Kurzava L; Flower K; Buvala H; Zhang H; Teegarden D; Camarillo I; Suderman M; Kuang S; Andrisani O; Flanagan JM; Stefanska B
    Carcinogenesis; 2016 Jul; 37(7):656-68. PubMed ID: 27207652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop.
    Sengupta D; Deb M; Rath SK; Kar S; Parbin S; Pradhan N; Patra SK
    Exp Cell Res; 2016 Aug; 346(2):176-87. PubMed ID: 27475839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Methylation in Breast Cancer Susceptibility and Treatment.
    Pouliot MC; Labrie Y; Diorio C; Durocher F
    Anticancer Res; 2015 Sep; 35(9):4569-74. PubMed ID: 26254344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of ARHI in breast and ovarian cancer cells.
    Yu Y; Fujii S; Yuan J; Luo RZ; Wang L; Bao J; Kadota M; Oshimura M; Dent SR; Issa JP; Bast RC
    Ann N Y Acad Sci; 2003 Mar; 983():268-77. PubMed ID: 12724231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
    Liu B; Song J; Luan J; Sun X; Bai J; Wang H; Li A; Zhang L; Feng X; Du Z
    Exp Biol Med (Maywood); 2016 Aug; 241(14):1531-9. PubMed ID: 27190263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells.
    Kim H; Park J; Jung Y; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Int J Oncol; 2010 Jun; 36(6):1563-72. PubMed ID: 20428781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation profiling of CpG islands in human breast cancer cells.
    Huang TH; Perry MR; Laux DE
    Hum Mol Genet; 1999 Mar; 8(3):459-70. PubMed ID: 9949205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant promoter CpG methylation and its translational applications in breast cancer.
    Xiang TX; Yuan Y; Li LL; Wang ZH; Dan LY; Chen Y; Ren GS; Tao Q
    Chin J Cancer; 2013 Jan; 32(1):12-20. PubMed ID: 22059908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation as a target of epigenetic therapeutics in cancer.
    Li KK; Li F; Li QS; Yang K; Jin B
    Anticancer Agents Med Chem; 2013 Feb; 13(2):242-7. PubMed ID: 22934696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of maspin gene expression in human breast cancers.
    Domann FE; Rice JC; Hendrix MJ; Futscher BW
    Int J Cancer; 2000 Mar; 85(6):805-10. PubMed ID: 10709100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
    Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
    Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.